BPC-157 for pain: what the human evidence shows
Bottom line: There is not enough reliable human evidence to know whether BPC-157 treats pain or speeds recovery. It is not an FDA-approved treatment for pain.
What is actually known?
- FDA staff found five small human studies using BPC-157. Only one involved knee pain: a retrospective report with 17 people.
- The studies were small, short, and provided limited safety information. They do not establish effectiveness for pain.
- A registered placebo-controlled hamstring-injury study includes pain as a secondary measure, but a trial registration is not a result.
Why the online claims are stronger than the evidence
Many claims come from animal research or uncontrolled reports. Those can justify further study, but they cannot tell us whether a treatment works safely in typical patients.
Regulatory status
BPC-157 is not FDA-approved. FDA says it has limited safety information for proposed routes of administration and has identified concerns involving immune reactions, impurities, and product characterization.
Primary sources
- FDA briefing document on BPC-157-related bulk drug substances (July 2026)
- FDA list of bulk substances that may present significant safety risks
- ClinicalTrials.gov: BPC-157 for acute hamstring muscle strain repair
Last reviewed: August 11, 2026.